$24.31
1.38% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$24.31
+0.91 3.89% 1M
+1.35 5.88% 6M
+3.44 16.48% YTD
-3.05 11.15% 1Y
-12.38 33.74% 3Y
-12.31 33.62% 5Y
+15.67 181.50% 10Y
+20.54 544.49% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.34 1.38%
ISIN
US3723032062
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
$15.2b
Enterprise Value
$14.7b
Net debt
positive
Cash
$506.5m
Shares outstanding
63.3m
Valuation (TTM | estimate)
P/E
8.8 | 9.8
P/S
30.0 | 26.4
EV/Sales
29.0 | 25.6
EV/FCF
83.3
P/B
18.3
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
17.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$507.4m | $575.6m
EBITDA
$173.7m | $1.4b
EBIT
$163.8m | $1.2b
Net Income
$178.1m | $158.6m
Free Cash Flow
$176.6m
Growth (TTM | estimate)
Revenue
25.3% | 17.4%
EBITDA
32.4% | 710.8%
EBIT
26.9% | 663.1%
Net Income
43.5% | -11.2%
Free Cash Flow
44.2%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
34.2% | 237.0%
EBIT
32.3%
Net
35.1% | 27.6%
Free Cash Flow
34.8%
More
EPS
$2.8
FCF per Share
$2.8
Short interest
0.6%
Employees
3k
Rev per Employee
$180.0k
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Genmab - ADR forecast:

21x Buy
72%
7x Hold
24%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Genmab - ADR forecast:

Buy
72%
Hold
24%
Sell
3%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
507 507
25% 25%
100%
- Direct Costs 25 25
151% 151%
5%
483 483
22% 22%
95%
- Selling and Administrative Expenses 88 88
11% 11%
17%
- Research and Development Expense 226 226
21% 21%
44%
174 174
32% 32%
34%
- Depreciation and Amortization 9.88 9.88
384% 384%
2%
EBIT (Operating Income) EBIT 164 164
27% 27%
32%
Net Profit 178 178
44% 44%
35%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
13 days ago
Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Neutral
Seeking Alpha
18 days ago
Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-Founder, President & CEO Judith V.
Neutral
GlobeNewsWire
18 days ago
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 in patients with relapsed or refractory FL Rinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data prese...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today